留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

糖尿病治疗中多肽类药物新型缓控释给药制剂的研究进展

宣吉明 程玉松 高静 钟延强

宣吉明, 程玉松, 高静, 钟延强. 糖尿病治疗中多肽类药物新型缓控释给药制剂的研究进展[J]. 药学实践与服务, 2012, 30(1): 14-18,37. doi: 10.3969/j.issn.1006-0111.2012.01.004
引用本文: 宣吉明, 程玉松, 高静, 钟延强. 糖尿病治疗中多肽类药物新型缓控释给药制剂的研究进展[J]. 药学实践与服务, 2012, 30(1): 14-18,37. doi: 10.3969/j.issn.1006-0111.2012.01.004
XUAN Ji-ming, CHENG Yu-song, GAO Jing, ZHONG Yan-qiang. Developments of sustained and controlled release delivery systems of peptides in treatment of diabetes[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(1): 14-18,37. doi: 10.3969/j.issn.1006-0111.2012.01.004
Citation: XUAN Ji-ming, CHENG Yu-song, GAO Jing, ZHONG Yan-qiang. Developments of sustained and controlled release delivery systems of peptides in treatment of diabetes[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(1): 14-18,37. doi: 10.3969/j.issn.1006-0111.2012.01.004

糖尿病治疗中多肽类药物新型缓控释给药制剂的研究进展

doi: 10.3969/j.issn.1006-0111.2012.01.004

Developments of sustained and controlled release delivery systems of peptides in treatment of diabetes

  • 摘要: 多肽类降血糖药物具有模拟正常人的生理性胰岛素分泌的功能,并且其降糖作用与患者血糖水平有关,很少发生低血糖事件。现就治疗糖尿病的多肽类药物新型缓控释制剂作一综述。
  • [1] Mei LT, Choong PFM, Dass CR. Recent developments in liposomes, microparticles and nanoparticles for protein and peptide drug delivery[J]. Peptides, 2010, 31(1):184.
    [2] Park W, Na K. Polyelectrolyte complex of chondroitin sulfate and peptide with lower pI value in poly(lactide-co-glycolide) microsphere for stability and controlled release[J]. Colloids Surf. B Biointerfaces , 2009, 72 (2):193.
    [3] Duchêne D, Wouessidjewe D, Ponchel G. Cyclodextrins and carrier systems[J]. J Control Release, 1999, 62(1-2):263.
    [4] Challa R, Abuja A, Ali J, et al. Cyclodextrins in drug delivery: an updated review[J]. AAPS Pharmscitech, 2005, 6(2):E329.
    [5] Ungaro F, Villa Bianca R, Giovino C, et al. Insulin-loaded PLGA/cyclodextrin large porous particles with improved aerosolization properties: in vivo deposition and hypoglycaemic activity after delivery to rat lungs[J]. J Control Release, 2009, 135(1):25.
    [6] Agüeros M, Areses P, Campanero MA, et al. Bioadhesive properties and biodistribution of cyclodextrin-poly(anhydride) nanoparticles[J]. Eur J Pharm. Sci, 2009, 37(3-4):231.
    [7] Agüeros M, Zabaleta V, Espuelas S, et al. Increased oral bioavailability of paclitaxel by its encapsulation through complex formation with cyclodextrins in poly(anhydride) nanoparticles[J]. J Control Release, 2010, 145(1):2.
    [8] Sajeesh S, Sharma CP. Cyclodextrin-insulin complex encapsulated polymethacrylic acid based nanoparticles for oral insulin delivery[J]. Int J Pharm, 2006, 325(1-2):147.
    [9] Han YD, Tian HY, He P, et al. Insulin nanoparticle preparation and encapsulation into poly(lactic-co-glycolic acid) microspheres by using an anhydrous system[J]. Int J Pharm, 2009, 378(1-2):159.
    [10] Builders PF, Kunle OO, Okpaku LC, et al. Preparation and evaluation of mucinated sodium alginate microparticles for oral delivery of insulin[J]. Eur J Pharm Biopharm, 2008, 70(3):777.
    [11] Zhang YL, Wei W, Lv PP, et al. Preparation and evaluation of alginate-chitosan microspheres for oral delivery of insulin[J]. Eur J Pharm Biopharm, 2011, 77(1):11.
    [12] Sonia TA, Sharma CP. In vitro evaluation of N-(2-hydroxy) propyl-3-trimethyl ammonium chitosan for oral insulin delivery[J]. Carbohydrate Polymers, 2011, 84(1):103.
    [13] Pan Y, Xu H, Zhao HY, et al. Study on preparation and oral efficacy of insulin-loaded poly ( lactic-co-glycolic acid)nanoparticles[J] . Acta Pharm Sin (药学学报), 2002, 37(7):374.
    [14] Marco W, Wim EH , Wim J . Protein instability in poly(lactic2co2glycolic acid) nanoparticles[J]. Pharm Res, 2000, 17 (10) :1159.
    [15] Lehr CM, Bouwstra JA , Kok W, et al. Effects of the mucoadhesive polymer polycarbophil on the intestinal absorption of a peptide drug in the rat[J]. J Pharm Pharmacol, 1992, 44(2):402.
    [16] Pimienta C, Chouinard F, Labib A, et al. Effects of various poloxamer coatings on in vitro adhesion of isohexylcyanoacrylate nanospheres to rat ileal segments under liquid flow[J]. Int J Pharm, 1992, 80(1):1.
    [17] Pan Y, Zhao HY, Xu H, et al. Effect of experimental parameters on the encapsulation of insulin-loaded poly(lactide2co2glycolide) nanoparticles prepared by a double emulsion method[J]. J Chin Pharm Sci, 2002, 11(1):38.
    [18] Lee VH.Peptidase activities in absorptive mucosae[J].Biochem Soc, 1989, 17(3):937.
    [19] Jain AK, Chalasani KB, Khar RK, et al. Muco-adhesive multivesicular liposomes as an effective carrier for transmucosal insulin delivery[J]. J Drug Target, 2007, 15(6):417.
    [20] 杨天智, 王向涛, 阎雪莹, 等. 胰岛素柔性纳米脂质体的口腔给药研究[J]. 药学学报,2002, 37(11):885.
    [21] YIN DF, LU Y, ZHANG H, et al. Preparation of Glucagon-Like Peptide-1 Loaded PLGA Microspheres: Characterizations, Release Studies and Bioactivities in Vitro/in Vivo[J]. Chem Pharm Bull, 2008, 56(2):156.
    [22] Joseph J W, Kalitsky J, St-Pierre S, et al. Oral delivery of glucagon-like peptide-1 in modified polymer preparation normalizes basal glycaemia in diabetic bd/bd mice[J]. Diabetologia, 2000, 43(10):1319.
    [23] Gao ZH, Tang Y, Chen JQ, et al. A novel DPP-IV-resistant analog of glucagon-like peptide-1 (GLP-1): KGLP-1 alone or in combination with long-acting PLGA microspheres[J]. Peptides, 2009, 30(10):1874.
    [24] Sten Madsbad, Professor. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)-preclinical and clinical results. Best Practice & Research Clinical Endocrinology & Metabolism, 2009, 23(4):463.
    [25] Yang HJ, Park IS, Na K. Biocompatible microspheres based on acetylated polysaccharide prepared from water-in-oil-in-water (W1/O/W2) double-emulsion method for delivery of type II diabetic drug (exenatide)[J]. Colloids and Surfaces A: Physicochem Eng Aspects, 2009, 340(1-3):115.
    [26] Nguyen HN, Wey SP, Juang JH, et al. The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo[J]. Biomaterials, 2011, 32(10):2673.
    [27] Hanato J, Kuriyama K,et al. Liposomal formulations of glucagon-like peptide-1: Improved bioavailability and anti-diabetic effect[J]. Int J Pharm, 2009, 382(1-2):111.
    [28] Singh M, Shirley B, Bajwa K, et al. Controlled release of recombinant insulin-like growth factor from a novel formulation of polylactide-co-glycolide microparticles[J]. J Control Release, 2001, 70(1-2):21.
    [29] Chen FM, Zhao YM, Wu H, et al. Enhancement of periodontal tissue regeneration by locally controlled delivery of insulin-like growth factor-I from dextran-co-gelatin microspheres[J]. J Control Release, 2006, 114(2):209.
    [30] Champa Jayasuriya A.Kibbe S. Rapid biomineralization of chitosan microparticles to apply in bone regeneration[J]. J Mater Sci: Mater Med, 2010, 21(2):393.
  • [1] 宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅.  帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(7): 1-7. doi: 10.12206/j.issn.2097-2024.202303023
    [2] 丁华敏, 郭羽晨, 秦春霞, 宋志兵, 孙莉莉.  消风止痒颗粒通过降低白三烯水平对小鼠特应性皮炎急性瘙痒的治疗作用研究 . 药学实践与服务, 2024, 42(5): 211-216. doi: 10.12206/j.issn.2097-2024.202306031
    [3] 唐淑慧, 凤美娟, 薛智霞, 鲁桂华.  帕博利珠单抗治疗所致免疫相关不良反应与中医体质的相关性研究 . 药学实践与服务, 2024, 42(5): 217-222. doi: 10.12206/j.issn.2097-2024.202311029
    [4] 景凯, 杨慈荣, 张圳, 臧艺蓓, 刘霞.  黄芪甲苷衍生物治疗慢性心力衰竭小鼠的药效评价及作用机制研究 . 药学实践与服务, 2024, 42(5): 190-197. doi: 10.12206/j.issn.2097-2024.202310004
    [5] 张晶晶, 索丽娜, 郑兆红.  89例细菌性肝脓肿的临床特征及抗感染治疗分析 . 药学实践与服务, 2024, 42(6): 267-272. doi: 10.12206/j.issn.2097-2024.202302039
    [6] 马兹芬, 许维恒, 金煜翔, 薛磊.  食管癌的靶向治疗与免疫治疗研究进展 . 药学实践与服务, 2024, 42(6): 231-237. doi: 10.12206/j.issn.2097-2024.202306008
    [7] 陈炳辰, 佟达丰, 万苗, 闫飞虎, 姚建忠.  UPLC-MS/MS法测定小鼠血浆中紫杉醇脂肪酸酯前药及其药代动力学研究 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202404082
    [8] 徐飞, 陈瑾, 鲁育含, 李志勇.  肠道菌群参与糖尿病肾病的机制研究进展 . 药学实践与服务, 2024, 42(5): 181-184, 197. doi: 10.12206/j.issn.2097-2024.202312023
  • 加载中
计量
  • 文章访问数:  3095
  • HTML全文浏览量:  184
  • PDF下载量:  396
  • 被引次数: 0
出版历程
  • 收稿日期:  2011-05-22
  • 修回日期:  2011-12-15

糖尿病治疗中多肽类药物新型缓控释给药制剂的研究进展

doi: 10.3969/j.issn.1006-0111.2012.01.004

摘要: 多肽类降血糖药物具有模拟正常人的生理性胰岛素分泌的功能,并且其降糖作用与患者血糖水平有关,很少发生低血糖事件。现就治疗糖尿病的多肽类药物新型缓控释制剂作一综述。

English Abstract

宣吉明, 程玉松, 高静, 钟延强. 糖尿病治疗中多肽类药物新型缓控释给药制剂的研究进展[J]. 药学实践与服务, 2012, 30(1): 14-18,37. doi: 10.3969/j.issn.1006-0111.2012.01.004
引用本文: 宣吉明, 程玉松, 高静, 钟延强. 糖尿病治疗中多肽类药物新型缓控释给药制剂的研究进展[J]. 药学实践与服务, 2012, 30(1): 14-18,37. doi: 10.3969/j.issn.1006-0111.2012.01.004
XUAN Ji-ming, CHENG Yu-song, GAO Jing, ZHONG Yan-qiang. Developments of sustained and controlled release delivery systems of peptides in treatment of diabetes[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(1): 14-18,37. doi: 10.3969/j.issn.1006-0111.2012.01.004
Citation: XUAN Ji-ming, CHENG Yu-song, GAO Jing, ZHONG Yan-qiang. Developments of sustained and controlled release delivery systems of peptides in treatment of diabetes[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(1): 14-18,37. doi: 10.3969/j.issn.1006-0111.2012.01.004
参考文献 (30)

目录

    /

    返回文章
    返回